Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

Recently, Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources… ...

Chronic obstructive pulmonary disease (COPD) is a significant global health concern, ranking as the third-leading cause of mortality worldwide and affecting around 480 million people. 1,2 Its hallmark ...

From December 7 to December 10, 2024, hematologists and oncologists gathered in San Diego, California, to attend the 2024 American Society of Hematology (ASH) 66th Annual Meeting. ASH 2024 showcased ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

Sanofi announces update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study: Paris Friday, February 14, 2025, 12:00 Hrs [IST] A scheduled review of the E.mbrace p ...

Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

DAVENPORT & Co LLC increased its stake in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an ...

Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...